Immunogenicity Profile After COVID-19 Vaccination in Patients with Onco-hematological Diseases

Overview

Journal Einstein (Sao Paulo)

Specialty General Medicine

Date 2023 Mar 22

PMID 36946824

Authors

Joao Bosco de Almeida Neto

Inara Lucia Arce

Vera Lucia de Piratininga Figueiredo

Perla Vicari

Affiliations

Soon will be listed here.

Abstract

Objective: To evaluate the influence of onco-hematological pathologies on seroconversion to COVID-19 vaccines, in addition to the effects of chemotherapy treatment on this response.

Methods: The present study evaluated the immunogenic response of 76 patients with onco-hematological diseases to multiple vaccine platforms compared to 25 control individuals.

Results: Our results showed positive response rates of 74.02% in patients with onco-hematological diseases and 100% in controls. When analyzed according to etiological group, patients with lymphoproliferative disorders achieved a positive vaccine response rate of 58.7%, whereas those with myeloproliferative diseases achieved a 100% response rate. We also observed that patients previously exposed to COVID-19 presented a 75% increase in their antibody values after vaccination, and these values were 37% higher than those of patients who did not have such exposure. We found that patients who underwent B-lymphocyte-depleting therapy in the last 2 years before vaccination had a worse response rate of 18.75%.

Conclusion: Despite the immunosuppression of patients with onco-hematological diseases, caused by the biology of their diseases and treatment, benefit and safety in vaccinating these patients are observed, in view of the important recall immune response and incidence of adverse effects similar to those of the healthy population.

References

Parry H, McIlroy G, Bruton R, Ali M, Stephens C, Damery S . Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia. Blood Cancer J. 2021; 11(7):136. PMC: 8323747. DOI: 10.1038/s41408-021-00528-x. View

Stampfer S, Goldwater M, Jew S, Bujarski S, Regidor B, Daniely D . Response to mRNA vaccination for COVID-19 among patients with multiple myeloma. Leukemia. 2021; 35(12):3534-3541. PMC: 8320411. DOI: 10.1038/s41375-021-01354-7. View

Deepak P, Kim W, Paley M, Yang M, Carvidi A, Demissie E . Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 : A Prospective Cohort Study. Ann Intern Med. 2021; 174(11):1572-1585. PMC: 8407518. DOI: 10.7326/M21-1757. View

Singhal T . A Review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr. 2020; 87(4):281-286. PMC: 7090728. DOI: 10.1007/s12098-020-03263-6. View

Whitaker J, Parikh S, Shanafelt T, Kay N, Kennedy R, Grill D . The humoral immune response to high-dose influenza vaccine in persons with monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL). Vaccine. 2021; 39(7):1122-1130. PMC: 8189080. DOI: 10.1016/j.vaccine.2021.01.001. View

Bahuaud M, Bodilis H, Malphettes M, Landre A, Matondo C, Bouscary D . Immunogenicity and persistence of the 13-valent Pneumococcal Conjugate Vaccine (PCV13) in patients with untreated Smoldering Multiple Myeloma (SMM): A pilot study. Heliyon. 2017; 3(11):e00441. PMC: 5681344. DOI: 10.1016/j.heliyon.2017.e00441. View

Ludwig H, Sonneveld P, Facon T, San-Miguel J, Avet-Loiseau H, Mohty M . COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. Lancet Haematol. 2021; 8(12):e934-e946. PMC: 8553271. DOI: 10.1016/S2352-3026(21)00278-7. View

Benda M, Mutschlechner B, Ulmer H, Grabher C, Severgnini L, Volgger A . Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients. Br J Haematol. 2021; 195(4):523-531. PMC: 8444745. DOI: 10.1111/bjh.17743. View

Yri O, Torfoss D, Hungnes O, Tierens A, Waalen K, Nordoy T . Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. Blood. 2011; 118(26):6769-71. DOI: 10.1182/blood-2011-08-372649. View

10.

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y . Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395(10223):507-513. PMC: 7135076. DOI: 10.1016/S0140-6736(20)30211-7. View

11.

Cordonnier C, Einarsdottir S, Cesaro S, Di Blasi R, Mikulska M, Rieger C . Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019; 19(6):e200-e212. DOI: 10.1016/S1473-3099(18)30600-5. View

12.

Avivi I, Balaban R, Shragai T, Sheffer G, Morales M, Aharon A . Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma. Br J Haematol. 2021; 195(2):186-193. PMC: 8444771. DOI: 10.1111/bjh.17608. View

13.

Dhakal B, Abedin S, Fenske T, Chhabra S, Ledeboer N, Hari P . Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy. Blood. 2021; 138(14):1278-1281. PMC: 8332674. DOI: 10.1182/blood.2021012769. View

14.

Achiron A, Mandel M, Dreyer-Alster S, Harari G, Magalashvili D, Sonis P . Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord. 2021; 14:17562864211012835. PMC: 8072850. DOI: 10.1177/17562864211012835. View

15.

Pasiarski M, Sosnowska-Pasiarska B, Grywalska E, Stelmach-Goldys A, Kowalik A, Gozdz S . Immunogenicity And Safety Of The 13-Valent Pneumococcal Conjugate Vaccine In Patients With Monoclonal Gammopathy Of Undetermined Significance - Relationship With Selected Immune And Clinical Parameters. Clin Interv Aging. 2019; 14:1741-1749. PMC: 6790629. DOI: 10.2147/CIA.S220423. View

16.

Fukatsu Y, Nagata Y, Adachi M, Yagyu T, Ono T . Serum IgM levels independently predict immune response to influenza vaccine in long-term survivors vaccinated at >1 year after undergoing allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2016; 105(5):638-645. DOI: 10.1007/s12185-016-2163-3. View

17.

Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A . Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients. N Engl J Med. 2021; 385(7):661-662. PMC: 8262620. DOI: 10.1056/NEJMc2108861. View

18.

Tan A, Linster M, Tan C, Bert N, Chia W, Kunasegaran K . Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell Rep. 2021; 34(6):108728. PMC: 7826084. DOI: 10.1016/j.celrep.2021.108728. View

19.

Ollila T, Lu S, Masel R, Zayac A, Paiva K, Rogers R . Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease. JAMA Oncol. 2021; 7(11):1714-1716. PMC: 8358793. DOI: 10.1001/jamaoncol.2021.4381. View

20.

Pleyer C, Ali M, Cohen J, Tian X, Soto S, Ahn I . Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines. Blood. 2020; 137(2):185-189. PMC: 7820878. DOI: 10.1182/blood.2020008758. View